Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
420 questions in 57 reviews · Gut
current versionsNo studies 420 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Infliximab combined with purine analogues vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Infliximab vs purine analogues Clinical relapse · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy Clinical remission · people with mild‐to‐moderate ulcerative colitis based on Truelove and Witts criteria Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy Quality of life · people with mild‐to‐moderate ulcerative colitis based on Truelove and Witts criteria Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy Total adverse events · people with mild‐to‐moderate ulcerative colitis based on Truelove and Witts criteria Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy Withdrawals due to adverse events · people with mild‐to‐moderate ulcerative colitis based on Truelove and Witts criteria Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Clinical relapse (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Clinical improvement · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Total adverse events · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs synbiotics Clinical relapse (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs synbiotics Clinical improvement · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs synbiotics Total adverse events · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs placebo Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10) Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Quality of life · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Clinical improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Endoscopic improvement at study endpoint (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Withdrawals due to adverse events at 26 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Cromolyn sodium vs placebo Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |